Anifrolumab in breastfeeding mothers with lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study is looking at how the lupus medicine anifrolumab passes into breast milk and affects mothers and their babies. It is for women who are already taking anifrolumab for lupus and are breastfeeding a baby born at 32 weeks or later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have moderate or severe lupus (SLE) and are currently taking anifrolumab.
- You are breastfeeding or pumping breast milk for your baby, and have been for at least 4 weeks.
- Your baby was born at 32 weeks or later, and their weight is above the 10th percentile for their age.
- You have not had lupus kidney inflammation in the last year, and have no history of breast cancer or breast surgery that affects breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information on pregnancy outcomes in women who took the drug anifrolumab during pregnancy or within 16 weeks before conception. It helps researchers understand how the drug may affect pregnancy and the baby.
This study looks at pregnancy outcomes in women with lupus (SLE) who were or were not treated with the drug anifrolumab. It helps understand if anifrolumab is safe to use during pregnancy.
This study tracks the health of pregnant women with moderate to severe lupus who have been treated with anifrolumab, compared to those treated with other lupus medications. It aims to understand how these treatments affect both mother and baby.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
This trial tests anifrolumab, given as a shot under the skin or through a vein, to see how it works in people with lupus. It may help if you have active lupus symptoms and are on standard treatments.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.